All In Biotech

Drug Trial Radar · NCT07258121

Study of ZGGS34 in Participants With Advanced Solid Tumors

A Phase 1/2 Dose Escalation and Cohort Expansion Study of the Tolerability, Safety, Efficacy, and Pharmacokinetics of ZGGS34 in Participants With Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: Apr 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

400

Planned (sponsor's estimate)

Start

Dec 31, 2025

Primary completion

Dec 2028

Study completion Dec 2028

Sponsor

Sponsor type
Industry
First posted
Dec 2, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, open-label Phase 1/2 study in participants with advanced solid tumors. The study consists of two parts: Part 1 is a dose-escalation phase to evaluate the safety and tolerability of ZGGS34 in advanced solid tumor participants; Part 2 is a cohort-expansion phase to assess the efficacy and safety of ZGGS34 (± chemotherapy) in selected MUC17-positive advanced solid tumor participants.

Conditions

  • Solid Tumor

Interventions

  • ZG006Biological

    ZG006 will be administered as an intravenous (IV) infusion.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The incidence of dose-limiting toxicity (DLT)Time frame: Up to 28 days
  2. Incidence of Treatment-emergent adverse events (TEAEs)Time frame: Up to 2 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Henan Cancer Hospital

    Zhengzhou, Henan, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.